Answers are grounded in this paper and cite their sources.
INTRODUCTION: Recent reports have suggested that selective COX-2 inhibition may be sufficient for the prevention of heterotopic ossification. METHODS: We performed a randomized controlled study to evaluate the effect of the selective COX-2 inhibitor rofecoxib compared to that of indomethacin on the incidence and extent of heterotopic ossification in patients who had undergone hip replacement surgery. 50 patients received a daily dose of 25 mg rofecoxib and 50 patients received a daily dose of 100 mg indomethacin (25, 25, and 50 mg). RESULTS: No ossifications were found in 48 patients. Grade-II ossifications were seen in 5/46 patients in the rofecoxib group and in 6/50 patients in the indomethacin group. Grade-III and grade-IV ossifications were seen in 3/46 patients in the rofecoxib group only. The differences were not statistically significant. The study medication had to be discontinued in 2 patients in the indomethacin group, due to dyspepsia. INTERPRETATION: After short-term administration, the selective COX-2 inhibitor rofecoxib was effective in preventing heterotopic ossification after total hip arthroplasty.
No takes yet. Share an insight, caveat, or question.
Grohs et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: